CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection

CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection

Experts discuss sequencing treatments in the third-line setting or beyond for patients who have not received chimeric antigen receptor T-cell therapy (CAR T) previously, comparing bispecific antibodies, CAR T, and other agents like polatuzumab and tafasitamab, while also considering patient factors and disease characteristics when selecting among available CAR-T options (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], and…

Multiple Myeloma Treatment Is a Success Story. The Price Is Complex Treatment Decisions — and High Costs

Survival rates have improved as treatment advances have multiplied, including CAR-T and bispecific antibodies.

The so-called CARThemis-1, developed and validated in preclinical models by IBiS Sevilla, is not only designed specifically to attack more efficiently a key protein in multiple myeloma cells, known as BCMA, but also has the ability to express EGFR, thus facilitating its monitoring before and after infusion, and allowing its complete elimination in case of toxicity, by using a monoclonal antibody.